Viable screening targets related to the bacterial cell wall

Annals of the New York Academy of Sciences

Volumn 1277, Issue 1, 2013, Pages 29-53

  Silver, Lynn L ^a  

^a LL Silver Consulting LLC   (United States)

Author keywords

Antibacterial resistance; Antibacterial targets; Cell wall synthesis; Peptidoglycan synthesis; Validated inhibitors

Indexed keywords

ALAFOSFALIN; ALANINE RACEMASE; AMFOMYCIN; BACITRACIN; BAMBERMYCIN; BETA LACTAM; CYCLOSERINE; DEXTRO ALANINE DEXTRO ALANINE LIGASE; FOSFOMYCIN; FOSMIDOMYCIN; GAMMA GLUTAMYLTRANSFERASE; GLYCOSYLTRANSFERASE; ISOPRENOID; LACTIVICIN; MERSACIDIN; NISIN; OXIDOREDUCTASE; PEPTIDOGLYCAN; RAMOPLANIN; SORTASE; TEICHOIC ACID; TRANSFERASE; UDP N ACETYL ENOLPYRUVYL GLUCOSAMINE REDUCTASE; UDP N ACETYL GLUCOSAMINE ENOLPYRUVYLTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL CELL WALL; DRUG TRANSPORT; ESCHERICHIA COLI; LIPOGENESIS; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PATHOGENESIS; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; SCREENING;

EID: 84872839334     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12006     Document Type: Article

References (193)

1. Silver, L.L. 2012. Rational approaches to antibacterial discovery: pre-genomic directed and phenotypic screening. In Antibiotic Discovery and Development T.J. Dougherty & M.J. Pucci, Eds.: 33-75. Springer. New York
2. Gadebusch, H.H., E.O. Stapley & S.B. Zimmerman 1992. The discovery of cell wall active antibacterial antibiotics. Crit. Rev. Biotechnol. 12: 225-243.
3. Trias, J. & Z. Yuan 1999. Mining bacterial cell wall biosynthesis with new tools: multitarget screens. Drug Resist. Updat. 2: 358-362.
4. Wong, K., D. Kuo, R. Chabin, et al. 1998. Engineering a cell-free murein biosynthetic pathway: combinatorial enzymology in drug discovery. J. Am. Chem. Soc. 120: 13527-13528.
5. Silver, L.L. 2006. Does the cell wall of bacteria remain a viable source of targets for novel antibiotics. Biochem. Pharmacol. 71: 996-1005.
6. Baba, T., T. Ara, M. Hasegawa, et al. 2006. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the KEIO collection. Mol. Syst. Biol. 2: 1-11.
7. Becker, D., M. Selbach, C. Rollenhagen, et al. 2006. Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature 440: 303-307.
8. Payne, D.J., M.N. Gwynn, D.J. Holmes & D.L. Pompliano 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6: 29-40.
9. Deigan, K.E. & A. R. FerrÉ-D'AmarÉ 2011. Riboswitches: discovery of drugs that target bacterial gene-regulatory RNAs. Acc. Chem. Res. 44: 1329-1338.
10. Gwynn, M.N., A. Portnoy, S.F. Rittenhouse & D.J. Payne 2010. Challenges of antibacterial discovery revisited. Ann. N. Y. Acad. Sci. 1213: 5-19.
11. Livermore, D.M. 2011. Discovery research: the scientific challenge of finding new antibiotics. J. Antimicrob. Chemother. 66: 1941-1944.
12. Silver, L.L. 2011. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24: 71-109.
13. Silver, L.L. 2007. Multi-targeting by monotherapeutic antibacterials. Nat. Rev. Drug Discov. 6: 41-55.
14. Brotz-Oesterhelt, H. & N.A. Brunner 2008. How many modes of action should an antibiotic have Curr. Opin. Pharmacol. 8: 564-573.
15. Frey, K.M., K. Viswanathan, D.L. Wright & A.C. Anderson 2012. Prospective screening of novel antibacterial inhibitors of dihydrofolate reductase for mutational resistance. Antimicrob. Agents Chemother. 56: 3556-3562.
16. Gumbo, T., A. Louie, M.R. Deziel, et al. 2007. Concentration-dependent mycobacterium tuberculosis killing and prevention of resistance by Rifampin. Antimicrob. Agents Chemother. 51: 3781-3788.
17. Gumbo, T., A. Louie, M.R. Deziel, et al. 2004. Selection of a Moxifloxacin dose that suppresses drug resistance in mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190: 1642-1651.
18. Anacor Pharmaceuticals announces that GSK has discontinued clinical development of GSK2251052. Available at: http://investor.anacor.com/releasedetail.cfm?ReleaseID=711456 (accessed October 19, 2012).
19. Barreteau, H., A. Kovac, A. Boniface, et al. 2008. Cytoplasmic steps of peptidoglycan biosynthesis. FEMS Microbiol. Rev. 32: 168-207.
20. Bugg, T.D.H., D. Braddick, C.G. Dowson & D.I. Roper 2011. Bacterial cell wall assembly: still an attractive antibacterial target. Trends Biotechnol. 29: 167-173.
21. Kotnik, M., P.S. Anderluh & A. Prezelj 2007. Development of novel inhibitors targeting intracellular steps of peptidoglycan biosynthesis. Curr.Pharm. Design 13: 2283-2309.
22. Gautam, A., R. Vyas & R. Tewari 2011. Peptidoglycan biosynthesis machinery: a rich source of drug targets. Crit. Rev. Biotechnol. 31: 295-336.
23. O'Neill, A.J. & I. Chopra 2004. Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin. Investig. Drugs 13: 1045-1063.
24. Smith, M.W. & J.W. Payne 1990. Simultaneous exploitation of different peptide permeases by combinations of synthetic peptide smugglins can lead to enhanced antibacterial activity. FEMS Microbiol. Lett. 70: 311-316.
25. Curtiss, R., L.J. Charamella, C.M. Berg & P.E. Harris 1965. Kinetic and genetic analyses of D-cycloserine inhibition and resistance in Escherichia coli. J. Bacteriol. 90: 1238-1250.
26. Lundqvist, T., S.L. Fisher, G. Kern, et al. 2007. Exploitation of structural and regulatory diversity in glutamate racemases. Nature 447: 817-822.
27. Soldo, B., V. Lazarevic & D. Karamata 2002. tagO is involved in the synthesis of all anionic cell-wall polymers in Bacillus subtilis 168. Microbiology 148: 2079-2087.
28. Winn, M., R.J.M. Goss, K.-i. Kimura & T.D.H. Bugg 2010. Antimicrobial nucleoside antibiotics targeting cell wall assembly: recent advances in structure-function studies and nucleoside biosynthesis. Nat. Prod. Rep. 27: 279-304.
29. Isono, F. & M. Inukai 1991. Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis. Antimicrob. Agents Chemother. 35: 234-236.
30. Kimura, K., Y. Ikeda, S. Kagami, et al. 1998. Selective inhibition of the bacterial peptidoglycan biosynthesis by the new types of liposidomycins. J. Antibiot. 51: 1099-1104.
31. Fernandes, P.B., R.N. Swanson, D.J. Hardy, et al. 1989. Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. III. Microbiologic profile. J. Antibiot. 42: 521-526.
32. Denome, S.A., P.K. Elf, T.A. Henderson, et al. 1999. Escherichia coli mutants lacking all possible combinations of eight penicillin binding proteins: viability, characteristics, and implications for peptidoglycan synthesis. J. Bacteriol. 181: 3981-3993.
33. Macheboeuf, P., D.S. Fischer, T. Brown, Jr., et al. 2007. Structural and mechanistic basis of penicillin-binding protein inhibition by lactivicins. Nat. Chem. Biol. 3: 565-569.
34. Turk, S., O. Verlaine, T. Gerards, et al. 2011. New noncovalent inhibitors of penicillin-binding proteins from penicillin-resistant bacteria. PLoS ONE 6: e19418.
35. Rohmer, M., C. Grosdemange-Billiard, M. Seemann & D. Tritsch 2004. Isoprenoid biosynthesis as a novel target for antibacterial and antiparasitic drugs. Curr.Opin. Invest. Drugs 5: 154-162.
36. Schneider, T. & H.G. Sahl 2010. Lipid II and other bactoprenol-bound cell wall precursors as drug targets. Curr. Opin. Invest. Drugs 11: 157-164.
37. Wiedemann, I., E. Breukink, C. van Kraaij, et al. 2001. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J. Biol. Chem. 276: 1772-1779.
38. Breukink, E. & B. de Kruijff 2006. Lipid II as a target for antibiotics. Nat. Rev. Drug Discov. 5: 321-323.
39. Lo, M.C., H. Men, A. Branstrom, et al. 2000. A new mechanism of action proposed for ramoplanin. J. Amer. Chem. Soc. 122: 3540-3541.
40. Pace, J.L. & G. Yang 2006. Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol. 71: 968-980.
41. Leclercq, R., E. Derlot, J. Duval & P. Courvalin 1988. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. New Engl. J. Med. 319: 157-161.
42. Bugg, T.D.H., G.D. Wright, S. Dutka-Malen, et al. 1991. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30: 10408-10415.
43. Zhang, R., H.Y. Ou & C.T. Zhang 2004. DEG: a database of essential genes. Nucleic Acids Res. 32: D271-D272.
44. Kahan, F.M., J.S. Kahan, P.J. Cassidy & H. Kropp 1974. The mechanism of action of fosfomycin (phosphonomycin). Ann. N. Y. Acad. Sci. 235: 364-386.
45. Hendlin, D., E.O. Stapley, M. Jackson, et al. 1969. Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science 166: 122-123.
46. Winkler, H.H. 1973. Distribution of an inducible hexose-phosphate transport system among various bacteria. J. Bacteriol. 116: 1079-1081.
47. Castaneda-Garcia, A., A. Rodriguez-Rojas, J.R. Guelfo & J. Blazquez 2009. The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa. J. Bacteriol. 191: 6968-6974.
48. Nilsson, A.I., O.G. Berg, O. Aspevall, et al. 2003. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob. Agents Chemother. 47: 2850-2858.
49. Barbosa, M.D., G. Yang, J. Fang, et al. 2002. Development of a whole-cell assay for peptidoglycan biosynthesis inhibitors. Antimicrob Agents Chemother. 46: 943-946.
50. Baum, E.Z., D.A. Montenegro, L. Licata, et al. 2001. Identification and characterization of new inhibitors of the Escherichia coli MurA enzyme. Antimicrob Agents Chemother. 45: 3182-3188.
51. Eschenburg, S., M.A. Priestman, F.A. Abdul-Latif, et al. 2005. A novel inhibitor that suspends the induced fit mechanism of UDP-N-acetylglucosamine enolpyruvyl transferase (MurA). J. Biol. Chem. 280: 14070-14075.
52. Dunsmore, C.J., K. Miller, K.L. Blake, et al. 2008. 2-Aminotetralones: novel inhibitors of MurA and MurZ. Bioorg. Med. Chem. Lett. 18: 1730-1734.
53. Gautam, A., P. Rishi & R. Tewari 2011. UDP-N-acetylglucosamine enol pyruvyl transferase as a potential target for antibacterial chemotherapy: recent developments. Appl. Microbiol. Biotechnol. 92: 211-225.
54. Mizyed, S., A. Oddone, B. Byczynski, et al. 2005. UDP-N-acetylmuramic Acid (UDP-MurNAc) is a potent inhibitor of MurA (enolpyruvyl-UDP-GlcNAc synthase). Biochemistry 44: 4011-4017.
55. Andres, C.J., J.J. Bronson, S.V. D'Andrea, et al. 2000. 4-Thiazolidinones: novel inhibitors of the bacterial enzyme MurB. Bioorg. Med. Chem. Lett. 10: 715-717.
56. Bronson, J.J., K.L. DenBleyker, P.J. Falk, et al. 2003. Discovery of the first antibacterial small molecule inhibitors of MurB. Bioorg. Med. Chem. Lett. 13: 873-875.
57. Francisco, G.D., Z. Li, J.D. Albright, et al. 2004. Phenyl thiazolyl urea and carbamate derivatives as new inhibitors of bacterial cell-wall biosynthesis. Bioorg. Med. Chem. Lett. 14: 235-238.
58. Kutterer, K.M., J.M. Davis, G. Singh, et al. 2005. 4-Alkyl and 4, 4'-dialkyl 1, 2-bis(4-chlorophenyl)pyrazolidine-3, 5-dione derivatives as new inhibitors of bacterial cell wall biosynthesis. Bioorg. Med. Chem. Lett. 15: 2527-2531.
59. Proctor, R.A., S.C. Dalal, B. Kahl, et al. 2002. Two diarylurea electron transport inhibitors reduce Staphylococcus aureus hemolytic activity and protect cultured endothelial cells from lysis. Antimicrob. Agents Chemother. 46: 2333-2336.
60. Bouhss, A., D. Mengin-Lecreulx, D. Blanot, et al. 1997. Invariant amino acids in the Mur peptide synthetases of bacterial peptidoglycan synthesis and their modification by site-directed mutagenesis in the UDP-MurNAc:lL-alanine ligase from Escherichia coli. Biochemistry 36: 11556-11563.
61. El Zoeiby, A., F. Sanschagrin & R.C. Levesque 2003. Structure and function of the Mur enzymes: development of novel inhibitors. Mol. Microbiol. 47: 1-12.
62. Smith, C.A. 2006. Structure, function and dynamics in the mur family of bacterial cell wall ligases. J. Mol. Biol. 362: 640-655.
63. Tanner, M.E., S. Vaganay, J. van Heijenoort & D. Blanot 1996. Phosphinate inhibitors of the D-glutamic acid-adding enzyme of peptidoglycan biosynthesis. J. Org. Chem. 61: 1756-1760.
64. Zeng, B., K. Wong, D. Pompliano, et al. 1998. A phosphinate inhibitor of the mesodiaminopimelic acid-adding enzyme (MurE) of peptidoglycan biosynthesis. J. Org. Chem. 63: 10081-10086.
65. Gegnas, L.D., S.T. Waddell, R.M. Chabin, et al. 1998. Inhibitors of the bacterial cell wall biosynthesis enzyme MurD. Bioorg. Med. Chem. Lett. 8: 1643-1648.
66. Frlan, R., A. Kovac, D. Blanot, et al. 2008. Design and synthesis of novel N-benzylidenesulfonohydrazide inhibitors of MurC and MurD as potential antibacterial agents. Molecules 13: 11-30.
67. Sim, M.M., S.B. Ng, A.D. Buss, et al. 2002. Benzylidene rhodanines as novel inhibitors of UDP-N-acetylmuramate/L-alanine ligase. Bioorg. Med. Chem. Lett. 12: 697-699.
68. Tomašić, T., N. Zidar, M. Mueller-Premru, et al. 2010. Synthesis and antibacterial activity of 5-ylidenethiazolidin-4-ones and 5-benzylidene-4, 6-pyrimidinediones. Eur. J. Med. Chem. 45: 1667-72.
69. Zidar, N., T. Tomasic, R. Sink, et al. 2011. New 5-benzylidenethiazolidin-4-one inhibitors of bacterial MurD ligase: design, synthesis, crystal structures, and biological evaluation. Eur. J. Med. Chem. 46: 5512-5523.
70. Baell, J.B. & G.A. Holloway 2010. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53: 2719-2740.
71. Tomašić, T. & L. Peterlin Mašič 2012. Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation. Exp. Opin. Drug Disc. 7: 549-560
72. Antane, S., C.E. Caufield, W. Hu, et al. 2006. Pulvinones as bacterial cell wall biosynthesis inhibitors. Bioorg. Med. Chem. Lett. 16: 176-180.
73. Li, Z., G.D. Francisco, W. Hu, et al. 2003. 2-Phenyl-5, 6-dihydro-2H-thieno[3, 2-c]pyrazol-3-ol derivatives as new inhibitors of bacterial cell wall biosynthesis. Bioorg. Med. Chem. Lett. 13: 2591-2594.
74. Mansour, T.S., C.E. Caufield, B. Rasmussen, et al. 2007. Naphthyl tetronic acids as multi-target inhibitors of bacterial peptidoglycan biosynthesis. ChemMedChem. 2: 1414-1417.
75. Zawadzke, L.E., M. Norcia, C.R. Desbonnet, et al. 2008. Identification of an inhibitor of the MurC enzyme, which catalyzes an essential step in the peptidoglycan precursor synthesis pathway. Assay Drug Dev. Technol. 6: 95-103.
76. Stamper, G.F., K.L. Longenecker, E.H. Fry, et al. 2006. Structure-based optimization of MurF inhibitors. Chem. Biol. Drug Des. 67: 58-65.
77. Baum, E.Z., S.M. Crespo-Carbone, B.D. Foleno, et al. 2009. MurF inhibitors with antibacterial activity: effect on muropeptide levels. Antimicrob. Agents Chemother. 53: 3240-3247.
78. Silver, L.L. 2008. Are natural products still the best source for antibacterial discovery? The bacterial entry factor. Exp. Opin. Drug Disc. 3: 487-500.
79. Reitz, R.H., H.D. Slade & F.C. Neuhaus 1967. The biochemical mechanisms of resistance by Streptococci to the antibiotics D-cycloserine and O-carbamyl-D-serine* Biochemistry 6: 2561-2570.
80. Noda, M., Y. Kawahara, A. Ichikawa, et al. 2004. Self-protection mechanism in D-cycloserine-producing. Streptomyces lavendulae J. Biol. Chem. 279: 46143-46152.
81. Milligan, D.L., S.L. Tran, U. Strych, et al. 2007. The alanine racemase of Mycobacterium smegmatis is essential for growth in the absence of D-alanine. J. Bacteriol. 189: 8381-8386.
82. Sassetti, C.M., D.H. Boyd & E.J. Rubin 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48: 77-84.
83. Bruning, J.B., A.C. Murillo, O. Chacon, et al. 2011. Structure of the Mycobacterium tuberculosis D-alanine:D-alanine ligase, a target of the antituberculosis drug D-cycloserine. Antimicrob. Agents Chemother. 55: 291-301.
84. Feng, Z. & R.G. Barletta 2003. Roles of Mycobacterium smegmatis D-ala:D-ala ligase and D-ala racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine. Antimicrob. Agents Chemother. 47: 283-291.
85. Wargel, R.J., C.A. Shadur & F.C. Neuhaus 1970. Mechanism of D-cycloserine action: transport systems for D-alanine, D-cycloserine, L-alanine, and glycine. J. Bacteriol. 103: 778-788.
86. Caceres, N.E., N.B. Harris, J.F. Wellehan, et al. 1997. Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis. J. Bacteriol. 179: 5046-5055.
87. Atherton, F.R., M.J. Hall, C.H. Hassall, et al. 1979. Phosphonopeptides as antibacterial agents: mechanism of action of alaphosphin. Antimicrob. Agents Chemother. 15: 696-705.
88. Gibson, M.M., M. Price & C.F. Higgins 1984. Genetic characterization and molecular cloning of the tripeptide permease (tpp) genes of Salmonella typhimurium. J. Bacteriol. 160: 122-130.
89. Pucci, M.J., J.A. Thanassi, H.T. Ho, et al. 1995. Staphylococcus haemolyticus contains two D-glutamic acid biosynthetic activities, a glutamate racemase and a D-amino acid transaminase. J. Bacteriol. 177: 336-342.
90. Fisher, S.L. 2008. Glutamate racemase as a target for drug discovery. Microbial. Biotechnol. 1: 345-360.
91. de Dios, A., L. Prieto, J.A. Martín, et al. 2002. 4-Substituted D-glutamic acid analogues: The first potent inhibitors of glutamate racemase (MurI) enzyme with antibacterial activity. J. Med. Chem. 45: 4559-4570.
92. Geng, B., G. Basarab, J. Comita-Prevoir, et al. 2009. Potent and selective inhibitors of Helicobacter pylori glutamate racemase (MurI): pyridodiazepine amines. Bioorg. Med. Chem. Lett. 19: 930-936.
93. de Jonge, B.L.M., A. Kutschke, M. Uria-Nickelsen, et al. 2009. Pyrazolopyrimidinediones are selective agents for Helicobacter pylori that suppress growth through inhibition of glutamate racemase (MurI). Antimicrob. Agents Chemother. 53: 3331-3336.
94. Price, N.P. & F.A. Momany 2005. Modeling bacterial UDP-HexNAc: polyprenol-P HexNAc-1-P transferases. Glycobiology 15: 29R-42R.
95. Lehrman, M.A. 1994. Commentary: A family of UDP-GlcNAc/MurNAc: polyisoprenol-P GlcNAc/MurNAc-1-P transferases. Glycobiology 4: 768-771.
96. Lehrman, M.A. 1991. Biosynthesis of N-acetylglucosamine-P-P-dolichol, the committed step of asparagine-linked oligosaccharide assembly. Glycobiology 1: 553-562.
97. Yamaguchi, H., S. Sato, S. Yoshida, et al. 1986. Capuramycin, a new nucleoside antibiotic. Taxonomy, fermentation, isolation and characterization. J. Antibiot. 39: 1047-1053.
98. Rasmussen, B.A., L.A. McDonald, P.J. Petersen, et al. 2001. Muraymycins, novel peptidoglycan biosynthesis inhibitors: identification and characterization of a natural product inhibitor of the peptidoglycan synthetic enzyme MraY., abstr. #1162. In Proceedings of the 41st Annual ICAAC, December 16-19. Chicago, IL
99. Inukai, M., F. Isono & A. Takatsuki 1993. Selective inhibition of the bacterial translocase reaction in peptidoglycan synthesis by mureidomycins. Antimicrob. Agents Chemother. 37: 980-983.
100. Brandish, P.E., K.I. Kimura, M. Inukai, et al. 1996. Modes of action of tunicamycin, liposidomycin B, and mureidomycin A: inhibition of phospho-N-acetylmuramyl-pentapeptide translocase from Escherichia coli. Antimicrob. Agents Chemother. 40: 1640-1644.
101. Dini, C. 2005. MraY inhibitors as novel antibacterial agents. Curr. Top. Med. Chem. 5: 1221-1236.
102. Isono, F., T. Katayama, M. Inukai & T. Haneishi 1989. Mureidomycins A-D, novel peptidylnucleoside antibiotics with spheroplast forming activity. III. Biological properties. J. Antibiot. 42: 674-679.
103. Lomovskaya, O., A. Mistry, M. Warren & A. Lee 2001. Characterization of pacidamycin resistant mutants in Pseudomonas aeruginosa, abstr. A-34. In Proceedings of the 101st General Meeting of the American Society for Microbiology May 20-24. Orlando, FL
104. Helm, J.S., Y. Hu, L. Chen, et al. 2003. Identification of active-site inhibitors of MurG using a generalizable, high-throughput glycosyltransferase screen. J. Am. Chem. Soc. 125: 11168-11169.
105. Hu, Y., J.S. Helm, L. Chen, et al. 2004. Identification of selective inhibitors for the glycosyltransferase MurG via high-throughput screening. Chem. Biol. 11: 703-711.
106. Jiang, J., M.B. Lazarus, L. Pasquina, et al. 2012. A neutral diphosphate mimic crosslinks the active site of human O-GlcNAc transferase. Nat. Chem. Biol. 8: 72-77.
107. Bishop, W.R. & R.M. Bell 1985. Assembly of the endoplasmic reticulum phospholipid bilayer: the phosphatidylcholine transporter. Cell 42: 51-60.
108. Mohammadi, T., V. van Dam, R. Sijbrandi, et al. 2011. Identification of FtsW as a transporter of lipid-linked cell wall precursors across the membrane. EMBO J. 30: 1425-1432.
109. Ruiz, N. 2008. Bioinformatics identification of MurJ (MviN) as the peptidoglycan lipid II flippase in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 105: 15553-15557.
110. Fay, A. & J. Dworkin 2009. Bacillus subtilis homologs of MviN (MurJ), the putative Escherichia coli lipid II flippase, are not essential for growth. J. Bacteriol. 191: 6020-6028.
111. Mott, J.E., B.A. Shaw, J.F. Smith, et al. 2008. Resistance mapping and mode of action of a novel class of antibacterial anthranilic acids: evidence for disruption of cell wall biosynthesis. J. Antimicrob. Chemother. 62: 720-729.
112. Huber, J., R.G.K. Donald, S.H. Lee, et al. 2009. Chemical genetic identification of peptidoglycan inhibitors potentiating carbapenem activity against methicillin-resistant Staphylococcus aureus. Chem. Biol. 16: 837-848.
113. Spratt, B.G. 1994. Resistance to antibiotics mediated by target alterations. Science 264: 388-393.
114. Hamilton-Miller, J.M.T. 1999. β-Lactams: variations on a chemical theme, with some surprising biological results. J. Antimicrob. Chemother. 44: 729-734.
115. Page, M.G.P. 2012. Beta-lactam antibiotics. In Antibiotic Discovery and Development T.J. Dougherty & M.J. Pucci, Eds.: 79-117. Springer. New York
116. Nozaki, Y., N. Katayama, S. Harada, et al. 1989. Lactivicin, a naturally occurring non-beta-lactam antibiotic having b-lactam-like action: biological activities and mode of action. J. Antibiot. 42: 84-93.
117. Harada, S., S. Tsubotani, T. Hida, et al. 1988. Chemistry of a new antibiotic: lactivicin. Tetrahedron 44: 6589-6606.
118. Nozaki, Y., N. Katayama, H. Ono, et al. 1987. Binding of a non-b-lactam antibiotic to penicillin-binding proteins. Nature 325: 179-180.
119. Zervosen, A., W.P. Lu, Z. Chen, et al. 2004. Interactions between penicillin-binding proteins (PBPs) and two novel classes of PBP inhibitors, arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones. Antimicrob. Agents Chemother. 48: 961-969.
120. Zervosen, A., A. Bouillez, A. Herman, et al. 2012. Synthesis and evaluation of boronic acids as inhibitors of penicillin binding proteins of classes A, B and C. Bioorg. Med. Chem. Lett. 20: 3915-3924.
121. Contreras-Martel, C., A. Amoroso, E.C. Woon, et al. 2011. Structure-guided design of cell wall biosynthesis inhibitors that overcome b-lactam resistance in Staphylococcus aureus (MRSA). ACS Chem. Biol. 6: 943-951.
122. Pechenov, A., M.E. Stefanova, R.A. Nicholas, et al. 2003. Potential transition state analogue inhibitors for the penicillin-binding proteins. Biochemistry 42: 579-588.
123. Toney, J.H., G.G. Hammond, B. Leiting, et al. 1998. Soluble penicillin-binding protein 2a: b-lactam binding and inhibition by non-b-lactams using a 96-well format. Anal. Biochem. 255: 113-119.
124. Shilabin, A.G., L. Dzhekieva, P. Misra, et al. 2012. 4-Quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins. ACS Med. Chem. Lett. 3: 592-595.
125. Reed, P., H. Veiga, A.M. Jorge, et al. 2011. Monofunctional transglycosylases are not essential for Staphylococcus aureus cell wall synthesis. J. Bacteriol. 193: 2549-2556.
126. Ostash, B. & S. Walker 2010. Moenomycin family antibiotics: chemical synthesis, biosynthesis, and biological activity. Nat. Prod. Rep. 27: 1594-617.
127. Derouaux, A., B. Wolf, C. Fraipont, et al. 2008. The monofunctional glycosyltransferase of Escherichia coli localizes to the cell division site and interacts with penicillin-binding protein 3, FtsW, and FtsN. J. Bacteriol. 190: 1831-1834.
128. Baizman, E.R., A.A. Branstrom, C.B. Longley, et al. 2000. Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylase. Microbiology 146: 3129-3140.
129. Halliday, J., D. McKeveney, C. Muldoon, et al. 2006. Targeting the forgotten transglycosylases. Biochem. Pharmacol. 71: 957-967.
130. Cheng, T.J., M.T. Sung, H.Y. Liao, et al. 2008. Domain requirement of moenomycin binding to bifunctional transglycosylases and development of high-throughput discovery of antibiotics. Proc. Natl Acad. Sci. U. S. A. 105: 431-436.
131. DeCenzo, M., M. Kuranda, S. Cohen, et al. 2002. Identification of compounds that inhibit late steps of peptidoglycan synthesis in bacteria. J Antibiot (Tokyo) 55: 288-295.
132. Singh, S.B., K. Young & L. Miesel 2011. Screening strategies for discovery of antibacterial natural products. Exp. Rev. Anti-Infect. Ther. 9: 589-613.
133. Ostash, B., A. Saghatelian & S. Walker 2007. A streamlined metabolic pathway for the biosynthesis of moenomycin A. Chem. Biol. 14: 257-267.
134. Sung, M.T., Y.T. Lai, C.Y. Huang, et al. 2009. Crystal structure of the membrane-bound bifunctional transglycosylase PBP1b from Escherichia coli. Proc. Natl Acad. Sci. U. S. A. 106: 8824-8829.
135. Lovering, A.L., L.H. de Castro, D. Lim & N.C. Strynadka 2007. Structural insight into the transglycosylation step of bacterial cell-wall biosynthesis. Science 315: 1402-1405.
136. Huang, C.-Y., H.-W. Shih, L.-Y. Lin, et al. 2012. Crystal structure of Staphylococcus aureus transglycosylase in complex with a lipid II analog and elucidation of peptidoglycan synthesis mechanism. Proc. Natl Acad. Sci. U. S. A. 109: 6496-6501.
137. Gampe, C.M., H. Tsukamoto, T.-S.A. Wang, et al. 2011. Modular synthesis of diphospholipid oligosaccharide fragments of the bacterial cell wall and their use to study the mechanism of moenomycin and other antibiotics. Tetrahedron 67: 9771-9778.
138. Testa, C.A. & M.J. Brown 2003. The methylerythritol phosphate pathway and its significance as a novel drug target. Curr. Pharm. Biotechnol. 4: 248-259.
139. Okuhara, M., Y. Kuroda, T. Goto, et al. 1980. Studies on new phosphonic acid antibiotics. I. FR-900098, isolation and characterization. J. Antibiot. 33: 13-17.
140. Okuhara, M., Y. Kuroda, T. Goto, et al. 1980. Studies on new phosphonic acid antibiotics. III. Isolation and characterization of FR-31564, FR-32863 and FR-33289. J. Antibiot. 33: 24-28.
141. Rohmer, M., M. Seemann, S. Horbach, et al. 1996. Glyceraldehyde 3-phosphate and pyruvate as precursors of isoprenic units in an alternative non-mevalonate pathway for terpenoid biosynthesis. J. Amer.Chem. Soc. 118: 2564-2566.
142. Lell, B., R. Ruangweerayut, J. Wiesner, et al. 2003. Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob. Agents Chemother. 47: 735-738.
143. Sakamoto, Y., S. Furukawa, H. Ogihara & M. Yamasaki 2003. Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli. Biosci. Biotechnol. Biochem. 67: 2030-2033.
144. Zhang, B., K.M. Watts, D. Hodge, et al. 2011. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling. Biochemistry 50: 3570-3577.
145. McKenney, E.S., M. Sargent, H. Khan, et al. 2012. Lipophilic prodrugs of FR900098 are antimicrobial against Francisella novicida in vivo and in vitro and show GlpT independent efficacy. PLoS ONE 7: e38167.
146. Jackson, E. & C. Dowd 2012. Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr): a review of the synthesis and biological evaluation of recent inhibitors. Curr. Top. Med. Chem. 12: 706-728.
147. Uh, E., E.R. Jackson, G. San Jose, et al. 2011. Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. Bioorg. Med. Chem. Lett. 21: 6973-6976.
148. Guo, R.T., R. Cao, P.H. Liang, et al. 2007. Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc. Natl Acad. Sci. U. S. A. 104: 10022-10027.
149. Zhang, Y., F.Y. Lin, K. Li, et al. 2012. HIV-1 integrase inhibitor-inspired antibacterials targeting isoprenoid biosynthesis. ACS Med. Chem. Lett. 3: 402-406.
150. El Ghachi, M., A. Derbise, A. Bouhss & D. Mengin-Lecreulx 2005. Identification of multiple genes encoding membrane proteins with undecaprenyl pyrophosphate phosphatase (UppP) activity in Escherichia coli. J. Biol. Chem. 280: 18689-18695.
151. Park, J.T. & T. Uehara 2008. How bacteria consume their own exoskeletons (turnover and recycling of cell wall peptidoglycan). Microbiol. Mol. Biol. Rev. 72: 211-227
152. West, R., D. Clarke & E. Kennedy 1938. The concentration of glucosamine in normal and pathological sera. J. Clin. Invest. 17: 173-178.
153. Mengin-Lecreulx, D. & J. van Heijenoort 1996. Characterization of the essential gene glmM encoding phosphoglucosamine mutase in Escherichia coli. J. Biol. Chem. 271: 32-39.
154. Mochalkin, I., S. Lightle, L. Narasimhan, et al. 2008. Structure of a small-molecule inhibitor complexed with GlmU from Haemophilus influenzae reveals an allosteric binding site. Protein Sci. 17: 577-582.
155. Pereira, M.P., J.E. Blanchard, C. Murphy, et al. 2009. High-throughput screening identifies novel inhibitors of the acetyltransferase activity of Escherichia coli GlmU. Antimicrob. Agents Chemother. 53: 2306-2311.
156. Buurman, E.T., B. Andrews, N. Gao, et al. 2011. In vitro validation of the acetyl transferase activity of GlmU as an antibacterial target in Haemophilus influenzae. J. Biol. Chem. 286: 40734-40742.
157. Green, O.M., A.R. McKenzie, A.B. Shapiro, et al. 2012. Inhibitors of acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). Part 1: Hit to lead evaluation of a novel arylsulfonamide series. Bioorg. Med. Chem. Let. 22: 1510-1519.
158. Brötz, H., G. Bierbaum, K. Leopold, et al. 1998. The Lantibiotic Mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob. Agents Chemother. 42: 154-160.
159. Ruzin, A., G. Singh, A. Severin, et al. 2004. Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria. Antimicrob. Agents Chemother. 48: 728-738.
160. Castiglione, F., A. Lazzarini, L. Carrano, et al. 2008. Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chem. Biol. 15: 22-31.
161. Donadio, S., S. Maffioli, P. Monciardini, et al. 2010. Antibiotic discovery in the twenty-first century: current trends and future perspectives. J. Antibiot. 63: 423-430.
162. Field, D., M. Begley, P.M. O'Connor, et al. 2012. Bioengineered Nisin A derivatives with enhanced activity against both gram positive and gram negative pathogens. PLoS ONE 7: e46884.
163. Walker, S., L. Chen, Y. Hu, et al. 2005. Chemistry and biology of ramoplanin: A lipoglycodepsipeptide with potent antibiotic activity. Chem. Rev. 105: 449-476.
164. Fang, X., K. Tiyanont, Y. Zhang, et al. 2006. The mechanism of action of ramoplanin and enduracidin. Mol. BioSyst. 2: 69-76.
165. Zhanel, G.G., D. Calic, F. Schweizer, et al. 2010. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70: 859-886
166. Siewert, G. & J.L. Strominger 1967. Bacitracin: an inhibitor of the dephosphorylation of lipid pyrophosphate, an intermediate in the biosynthesis of the peptidoglycan of bacterial cell walls. Proc. Natl Acad. Sci. U. S. A. 57: 767-773.
167. Tanaka, H., R. Ōiwa, S. Matusukura & S. Ōmura 1979. Amphomycin inhibits phospho-N-acetylmuramyl-pentapeptide translocase in peptidoglycan synthesis of Bacillus. Biochem. Biophys. Res. Comm. 86: 902-908.
168. Cain, B.D., P.J. Norton, W. Eubanks, et al. 1993. Amplification of the bacA gene confers bacitracin resistance to Escherichia coli. J. Bacteriol. 175: 3784-3789.
169. Miller, J.H., R. K. McDonald & N.W. Shock 1950. The effect of bacitracin on renal function. J. Clin. Invest. 29: 389.
170. Baddiley, J. 1973. Lipid intermediates in the biosynthesis of bacterial cell wall components. Biochem. Soc. Trans 1: 1026-1028.
171. Jonsson, I.M., S.K. Mazmanian, O. Schneewind, et al. 2003. The role of Staphylococcus aureus sortase A and sortase B in murine arthritis. Microbes Infect. 5: 775-780.
172. Weidenmaier, C., A. Peschel, Y.-Q. Xiong, et al. 2005. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. J. Infect. Dis. 191: 1771-1777.
173. Weidenmaier, C., J.F. Kokai-Kun, E. Kulauzovic, et al. 2008. Differential roles of sortase-anchored surface proteins and wall teichoic acid in Staphylococcus aureus nasal colonization. Intl. J. Med. Microbiol. 298: 505-513.
174. Maresso, A.W. & O. Schneewind 2008. Sortase as a target of anti-infective therapy. Pharmacol. Rev. 60: 128-141.
175. Clancy, K.W., J.A. Melvin & D.G. McCafferty 2010. Sortase transpeptidases: insights into mechanism, substrate specificity, and inhibition. Peptide Sci. 94: 385-396.
176. Maresso, A.W., R. Wu, J.W. Kern, et al. 2007. Activation of inhibitors by sortase triggers irreversible modification of the active site. J. Biol. Chem. 282: 23129-23139.
177. Suree, N., S.W. Yi, W. Thieu, et al. 2009. Discovery and structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors. Bioorg. Med. Chem. 17: 7174-7185.
178. D'Elia, M.A., K.E. Millar, A.P. Bhavsar, et al. 2009. Probing teichoic acid genetics with bioactive molecules reveals new interactions among diverse processes in bacterial cell wall biogenesis. Chem. Biol. 16: 548-556.
179. Swoboda, J.G., J. Campbell, T.C. Meredith & S. Walker 2010. Wall teichoic acid function, biosynthesis, and inhibition. Chembiochem 11: 35-45.
180. Swoboda, J.G., T.C. Meredith, J. Campbell, et al. 2009. Discovery of a small molecule that blocks wall teichoic acid biosynthesis in Staphylococcus aureus. ACS Chem. Biol. 4: 875-883.
181. Moellering, R.C., Jr. 2011. Discovering new antimicrobial agents. Intl. J. Antimicrob. Agents 37: 2-9.
182. Fabret, C. & J.A. Hoch 1998. A two-component signal transduction system essential for growth of Bacillus subtilis: Implications for anti-infective therapy. J. Bacteriol. 180: 6375-6383.
183. Dubrac, S. & T. Msadek 2008. Tearing down the wall: Peptidoglycan metabolism and the WalK/WalR (YycG/YycF) essential two-component system. In Bacterial Signal Transduction: Networks and Drug Targets. R. Utsumi, Eds.: 214-228. Landes Bioscience and Springer Science+Business Media. New York, NY.
184. Wagner, C., A.d. Saizieu, H.-J. Schönfeld, et al. 2002. Genetic analysis and functional characterization of the Streptococcus pneumoniaevic operon. Infect. Immun. 70: 6121-6128.
185. Winkler, M.E. & J.A. Hoch 2008. Essentiality, bypass, and targeting of the YycFG (VicRK) two-component regulatory system in gram-positive bacteria. J. Bacteriol. 190: 2645-2648.
186. Fukuchi, K., Y. Kasahara, K. Asai, et al. 2000. The essential two-component regulatory system encoded by yycF and yycG modulates expression of the ftsAZ operon in Bacillus subtilis. Microbiology 146: 1573-1583.
187. Ng, W.-L., G.T. Robertson, K.M. Kazmierczak, et al. 2003. Constitutive expression of PcsB suppresses the requirement for the essential VicR (YycF) response regulator in Streptococcus pneumoniae R6. Mol. Microbiol. 50: 1647-1663.
188. Delaune, A., O. Poupel, A. Mallet, et al. 2011. Peptidoglycan crosslinking relaxation plays an important role in Staphylococcus aureus WalKR-dependent cell viability. PLoS ONE 6: e17054.
189. Watanabe, T., Y. Hashimoto, K. Yamamoto, et al. 2003. Isolation and characterization of inhibitors of the essential histidine kinase, YycG in Bacillus subtilis and Staphylococcus aureus. J. Antibiot. 56: 1045-1052.
190. Okada, A., M. Igarashi, T. Okajima, et al. 2010. Walkmycin B targets WalK (YycG), a histidine kinase essential for bacterial cell growth. J. Antibiot. 63: 89-94.
191. Watanabe, T., M. Igarashi, T. Okajima, et al. 2012. Isolation and characterization of signermycin B, an antibiotic that targets the dimerization domain of histidine kinase WalK. Antimicrob. Agents Chemother. 56: 3657-3663.
192. Gotoh, Y., A. Doi, E. Furuta, et al. 2010. Novel antibacterial compounds specifically targeting the essential WalR response regulator. J. Antibiot. 63: 127-134.
193. Matteï, P.-J., D. Neves & A. Dessen 2010. Bridging cell wall biosynthesis and bacterial morphogenesis. Curr. Opin. Struct. Biol. 20: 749-755.